Jun 2026 (Q1 FY27) — Aug 6, 2026
Immunovant Q1 FY27 — Busy Pipeline Ahead of Key Readouts and Launch
Read the full callImmunovant (IMVT) earnings
- Jun 2026
- Jun 2026 (Q1 FY27)
- Mar 2026
Immunovant earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -153 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$27.51 −1.40% · −$0.39
Performance +57.3% 1Y
1Y: $17.49 on 14 Oct 2025 → $27.51. High $44.96 (19 Aug 2026), low $17.41 (16 Oct 2025).
- Previous close
- $27.9
- 52-week range
- $17.41 – $44.96
- One year
- +53.43%
Overview
- Symbol
- IMVT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Immunovant earnings calls (IMVT)
Financials
What the filings say
Net profit, year on year: −27% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Profit before tax | -109 | -111 | -106 | -120 | -126 | -109 | -151 | -153 |
| Tax rate | −0.1% | −0.1% | −0.6% | −0.8% | −0.5% | −1.4% | 1.9% | 0.0% |
| Net profit | -109 | -111 | -106 | -121 | -127 | -111 | -148 | -153 |
| EPS ($ per share) | -0.74 | -0.76 | — | -0.71 | -0.73 | -0.61 | — | -0.75 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -25 | -91 | -199 | -355 | -566 | -826 | -1,240 | -1,745 |
| Total liabilities | 6 | 15 | 21 | 46 | 43 | 49 | 69 | 104 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Total assets | 14 | 109 | 412 | 516 | 406 | 666 | 776 | 957 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29 | -53 | -83 | -106 | -188 | -214 | -376 | -407 |
| Cash from investing | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -0 |
| Cash from financing | 36 | 147 | 383 | 200 | 71 | 472 | 454 | 596 |
| Net cash flow | 7 | 94 | 300 | 94 | -117 | 259 | 79 | 188 |
| Capital expenditure | -0 | -0 | -0 | -0 | -0 | -0 | -1 | -0 |
| Free cash flow | -29 | -53 | -84 | -106 | -188 | -215 | -377 | -407 |
Insider filings
91 filings between Oct 22, 2025 and Oct 7, 2026.
Open market
decisions to buy or sellPurchases
$350.00M
1 purchase by 1 insider
Sales
$16.34M
62 sales by 10 insiders
16% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
Also filed: 3 dispositions to the issuer.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Roivant Sciences Ltd. | $350.00M | — | Dec 12, 2025 |
| Fromkin Andrew J. | — | $7.96M | May 28, 2026 |
| Stout Jay S | — | $2.37M | Oct 7, 2026 |
| Gloria Melanie | — | $1.67M | Oct 7, 2026 |
| Van Tuyl Christopher | — | $1.46M | Oct 7, 2026 |
| Girao Tiago | — | $1.41M | Jul 23, 2026 |
| Venker Eric | — | $581.4K | Oct 2, 2026 |
| Pande Atul | — | $424.6K | Aug 28, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 1,327 | $42.5K |
| Oct 7, 2026 | Gloria Melanie Chief Operating Officer | Sale | 2,241 | $71.8K |
| Oct 7, 2026 | Stout Jay S Chief Technology Officer | Sale | 2,213 | $70.9K |
| Oct 7, 2026 | Stout Jay S Chief Technology Officer | Sale | 1,596 | $51.2K |
| Oct 2, 2026 | Venker Eric Chief Executive Officer | Sale | 3,506 | $119.6K |
| Oct 1, 2026 | Venker Eric Chief Executive Officer | Disposition to issuer | 85,886 | $2.89M |
| Oct 1, 2026 | Venker Eric Chief Executive Officer | Option exercise | 92,187 | $1.33M |
| Sep 23, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 2,846 | $103.5K |
| Aug 28, 2026 | Pande Atul Director | Option exercise 10b5-1 plan | 1,500 | $12.6K |
| Aug 28, 2026 | Pande Atul Director | Sale 10b5-1 plan | 1,500 | $64.9K |
| Aug 20, 2026 | Gloria Melanie Chief Operating Officer | Sale | 3,056 | $135.0K |
| Jul 24, 2026 | Pande Atul Director | Option exercise 10b5-1 plan | 1,500 | $12.6K |
| Jul 24, 2026 | Pande Atul Director | Sale 10b5-1 plan | 1,500 | $59.7K |
| Jul 23, 2026 | Girao Tiago Chief Financial Officer | Sale | 6,798 | $263.0K |
| Jul 23, 2026 | Stout Jay S Chief Technology Officer | Sale | 2,857 | $110.5K |
| Jul 8, 2026 | Stout Jay S Chief Technology Officer | Sale | 105 | $4.2K |
| Jul 8, 2026 | Stout Jay S Chief Technology Officer | Sale | 1,906 | $75.3K |
| Jul 8, 2026 | Gloria Melanie Chief Operating Officer | Sale | 106 | $4.2K |
| Jul 8, 2026 | Gloria Melanie Chief Operating Officer | Sale | 1,930 | $76.3K |
| Jul 8, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 63 | $2.5K |
| Jul 8, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 1,143 | $45.2K |
| Jul 8, 2026 | Stout Jay S Chief Technology Officer | Sale | 77 | $3.1K |
| Jul 8, 2026 | Stout Jay S Chief Technology Officer | Sale | 1,399 | $55.3K |
| Jul 2, 2026 | Venker Eric Chief Executive Officer | Sale | 3,092 | $119.0K |
| Jul 1, 2026 | Venker Eric Chief Executive Officer | Disposition to issuer | 86,629 | $3.30M |
| Jul 1, 2026 | Venker Eric Chief Executive Officer | Option exercise | 92,188 | $1.33M |
| Jun 26, 2026 | Pande Atul Director | Option exercise 10b5-1 plan | 1,500 | $12.6K |
| Jun 26, 2026 | Stout Jay S Chief Technology Officer | Sale | 33,277 | $1.27M |
| Jun 26, 2026 | Gloria Melanie Chief Operating Officer | Sale | 2,966 | $115.5K |
| Jun 26, 2026 | Gloria Melanie Chief Operating Officer | Sale | 14,748 | $563.1K |
| Jun 26, 2026 | Stout Jay S Chief Technology Officer | Sale | 6,723 | $261.8K |
| Jun 26, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 2,842 | $110.7K |
| Jun 26, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 14,982 | $572.2K |
| Jun 26, 2026 | Van Tuyl Christopher Chief Legal Officer | Option exercise | 17,824 | $270.9K |
| Jun 26, 2026 | Girao Tiago Chief Financial Officer | Sale | 10,000 | $384.6K |
| Jun 26, 2026 | Pande Atul Director | Sale 10b5-1 plan | 1,500 | $57.0K |
| Jun 26, 2026 | Girao Tiago Chief Financial Officer | Option exercise | 10,000 | $159.0K |
| Jun 18, 2026 | Van Tuyl Christopher Chief Legal Officer | Sale | 2,634 | $93.2K |
| Jun 15, 2026 | Pande Atul Director | Sale 10b5-1 plan | 1,500 | $51.0K |
| Jun 15, 2026 | Pande Atul Director | Option exercise 10b5-1 plan | 1,500 | $12.6K |
| May 28, 2026 | Fromkin Andrew J. Director | Option exercise | 77,181 | $650.6K |
| May 28, 2026 | Fromkin Andrew J. Director | Option exercise | 71,492 | $567.6K |
| May 28, 2026 | Fromkin Andrew J. Director | Sale | 210,468 | $7.06M |
| May 28, 2026 | Fromkin Andrew J. Director | Option exercise | 31,668 | $158.0K |
| May 28, 2026 | Fromkin Andrew J. Director | Sale | 11,483 | $374.8K |
| May 28, 2026 | Fromkin Andrew J. Director | Option exercise | 16,260 | $239.0K |
| May 20, 2026 | Gloria Melanie Chief Operating Officer | Sale | 1,168 | $37.6K |
| May 20, 2026 | Gloria Melanie Chief Operating Officer | Sale | 249 | $7.6K |
| May 20, 2026 | Gloria Melanie Chief Operating Officer | Sale | 1,698 | $55.9K |
| May 20, 2026 | Pande Atul Director | Option exercise 10b5-1 plan | 6,000 | $50.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Immunovant, Inc.
Free account. Everything above stays public.
Write why you follow Immunovant, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading